The aim is to incorporate tumor characteristics, such as tumor stage, grade and estrogen receptor status, comorbidity and other geriatric parameters to predict breast cancer and other-cause mortality, but also focus on other relevant outcomes, such as toxicity and functional outcomes. This evidence concerns the gene ESR1 and breast carcinoma.